Clinical Trial Update: A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating Tecfidera (dimethyl fumarate) on multiple sclerosis disease activity and patient-reported outcomes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Tecfidera (dimethyl fumarate)

Snippet

Sponsor: Biogen | Conditions: Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis | Phase 4 | Status: COMPLETED